The SRM Institute of Science and Technology has been released the phase 3 result 2025 on its official website at srmist.edu.in. Check result using registration ID and password.

Known for its quick reload and solid design, the Model 3 became a trusted sidearm around the world. Learn how it helped build Smith & Wesson’s legacy.

Investing.com -- Viatris Inc. (NASDAQ: VTRS) stock fell 3.6% after the company announced that its Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint. The randomized, double ...

Charleston’s urban development is taking shape as the City’s Board of Architectural Review considers the conceptual plans for Phase 3 of the Courier Square project. July 9, 2025. (WCIV) ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA ...

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid ...

Itepekimab, an investigational monoclonal antibody for chronic obstructive pulmonary disease (COPD), demonstrated mixed results in a pair of phase 3 studies evaluating the treatment in former ...

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.

--Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc, today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 in pediatric and young ...

a Tyr Pharma (ATYR) announced that the last patient has completed their last visit in the Company’s Phase 3 EFZO-FIT study of its lead therapeutic candidate, efzofitimod, in patients with ...